These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17068112)

  • 21. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.
    Dickstein DL; Biron KE; Ujiie M; Pfeifer CG; Jeffries AR; Jefferies WA
    FASEB J; 2006 Mar; 20(3):426-33. PubMed ID: 16507760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
    Gaugler MN; Tracy J; Kuhnle K; Crameri A; Nitsch RM; Mohajeri MH
    FEBS Lett; 2005 Jan; 579(3):753-6. PubMed ID: 15670841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
    Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J
    Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.
    Tamura Y; Hamajima K; Matsui K; Yanoma S; Narita M; Tajima N; Xin KQ; Klinman D; Okuda K
    Neurobiol Dis; 2005 Nov; 20(2):541-9. PubMed ID: 15908227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.
    DeMattos RB; Bales KR; Cummins DJ; Dodart JC; Paul SM; Holtzman DM
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8850-5. PubMed ID: 11438712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.
    DeMattos RB; Bales KR; Cummins DJ; Paul SM; Holtzman DM
    Science; 2002 Mar; 295(5563):2264-7. PubMed ID: 11910111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative and mechanistic studies of Abeta immunotherapy.
    Golde TE; Das P; Levites Y
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):31-49. PubMed ID: 19275635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.
    Yamada K; Yabuki C; Seubert P; Schenk D; Hori Y; Ohtsuki S; Terasaki T; Hashimoto T; Iwatsubo T
    J Neurosci; 2009 Sep; 29(36):11393-8. PubMed ID: 19741145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.
    Yang J; Pattanayak A; Song M; Kou J; Taguchi H; Paul S; Ponnazhagan S; Lalonde R; Fukuchi K
    J Mol Neurosci; 2013 Feb; 49(2):277-88. PubMed ID: 22945846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.
    Ramakrishnan M; Kandimalla KK; Wengenack TM; Howell KG; Poduslo JF
    Biochemistry; 2009 Nov; 48(43):10405-15. PubMed ID: 19775170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.
    Levites Y; Funk C; Wang X; Chakrabarty P; McFarland KN; Bramblett B; O'Neal V; Liu X; Ladd T; Robinson M; Allen M; Carrasquillo MM; Dickson D; Cruz P; Ryu D; Li HD; Price ND; Ertekin-Taner N; Golde TE
    Mol Neurodegener; 2021 May; 16(1):32. PubMed ID: 33957936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease.
    Jin M; O'Nuallain B; Hong W; Boyd J; Lagomarsino VN; O'Malley TT; Liu W; Vanderburg CR; Frosch MP; Young-Pearse T; Selkoe DJ; Walsh DM
    Nat Commun; 2018 Jul; 9(1):2676. PubMed ID: 29992960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain.
    Chauhan NB; Siegel GJ; Lichtor T
    J Neurosci Res; 2001 Oct; 66(2):231-5. PubMed ID: 11592118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.
    Lemere CA; Spooner ET; LaFrancois J; Malester B; Mori C; Leverone JF; Matsuoka Y; Taylor JW; DeMattos RB; Holtzman DM; Clements JD; Selkoe DJ; Duff KE
    Neurobiol Dis; 2003 Oct; 14(1):10-8. PubMed ID: 13678662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.
    Klyubin I; Betts V; Welzel AT; Blennow K; Zetterberg H; Wallin A; Lemere CA; Cullen WK; Peng Y; Wisniewski T; Selkoe DJ; Anwyl R; Walsh DM; Rowan MJ
    J Neurosci; 2008 Apr; 28(16):4231-7. PubMed ID: 18417702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.